In addition, to select HER2 mutations serving as a primary oncogenic driver in NSCLC, these may also present as an acquired mechanism of resistance to EGFR tyrosine kinase inhibitor (TKI) treatment [5,6]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.